Evidence map›Paper›PMID 35962938›Full record

ReviewCurrent treatment options in oncology2022

Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.

Jenny Peng, Srikala Sridhar, Arlene Odelia Siefker-Radtke, Shamini Selvarajah, Di Maria Jiang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jenny PengDivision of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, 7-613, 700 University Avenue, Toronto, ON, M5G 2C1, Canada.
Srikala SridharDivision of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, 7-613, 700 University Avenue, Toronto, ON, M5G 2C1, Canada.
Arlene Odelia Siefker-RadtkeDivision of Medical Oncology, Department of Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shamini SelvarajahClinical Laboratory Genetics, Laboratory Medicine Program, University Health Network (UHN), Toronto General Hospital, Eaton Wing 11-444, 200 Elizabeth Street, Toronto, ON, Canada.
Di Maria JiangDivision of Medical Oncology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, 7-613, 700 University Avenue, Toronto, ON, M5G 2C1, Canada. di.jiang@uhn.ca.
University Health Network · CAThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementAs we come to better understand cancer genomics, we are increasingly shifting towards precision medicine. FGFR has been elucidated as one of the oncogenic driver pathways in urothelial carcinoma, leading to exciting targeted drug development. Although many agents are being investigated, erdafitinib is the only FGFR inhibitor currently approved by the FDA for treating platinum-refractory metastatic urothelial carcinoma harboring susceptible FGFR2/3 alterations, with seemingly higher response rates than second-line chemotherapy or immunotherapy. In this review, we summarize the clinical data supporting FGFR inhibition, ways to optimize its use in routine clinical practice including FGFR testing, dosing, and toxicity management. We also highlight ongoing efforts evaluating combination strategies and testing in earlier treatment settings to further expand this targeted therapeutic approach in urothelial carcinoma.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansImmunotherapyProtein Kinase InhibitorsProtein Kinase InhibitorsBladder cancerClinical trialErdafitinibFGFRTargeted therapyUrothelial cancer

Identifiers

PMID35962938
OpenAlexW4291202004

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.